Landmark Study Published in Archives of Facial Plastic Surgery Shows Benefits of SELPHYL® System Ultrapure PRFM
WAYNE, N.J., Jan. 10, 2012 /PRNewswire/ — A recent study evaluating the efficacy of the SELPHYL® System was published in Archives of Facial Plastic Surgery by Drs. Anthony P. Sclafani and Steven A. McCormick.[i]
The researchers set out to assess the changes in skin after injection of Selphyl, an ultrapure platelet-rich fibrin matrix (PRFM). Utilizing a small amount of the patient’s own blood, the system isolates and prepares PRFM for injection back into the patient. The process takes about 6 minutes and the resulting PRFM has a golden color that some physicians refer to as “liquid gold.”
In the 10-week study, four healthy adult volunteers were injected with PRFM in their upper arms. The study showed that as early as seven days after treatment, activated fibroblasts (collagen-producing cells) were identified and new collagen formation occurred. By 19 days, new blood vessels developed. Within three weeks, scientists observed stimulation of new fat cells called adipocytes, meaning PRFM has stimulated the body’s own production of what has been lost as a function of aging.
The study also notes that people treated with PRFM typically describe their skin as “softer” after 8 to 12 weeks.
“The benefits of PRFM to improve the skin’s tone and texture are now better understood at the tissue level,” stated Dr. Anthony P. Sclafani, the director of facial plastic surgery at the New York Eye and Ear Infirmary. “We’ve seen the rejuvenating effects of PRFM on patients last for more than a year — sometimes 18 to 24 months.”
Physicians have been using Selphyl® to prepare PRFM for a number of applications to address various unmet needs in plastic and reconstructive surgery, otolaryngology, orthopedics, cardiology and other medical specialties. Selphyl® has been shown to be safe and there have been no cases of granulomas, immune response or allergic reactions reported.
The simple in-office procedure is being used by over 350 physicians worldwide. More than 15,000 cases have been performed with Selphyl® since 2006. Selphyl® is only available through qualified healthcare practitioners including dermatologists and plastic surgeons.
Selphyl® is intended for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP can be mixed with autograft and allograft bone prior to the application to an orthopedic surgical site as deemed necessary by the clinical use requirements. http://www.Selphyl.com
The SELPHYL® System is manufactured by Cascade Medical Enterprises, LLC., an affiliate of Aesthetic Factors, LLC. Aesthetic Factors’ primary and only business is growth factor technology.
[i] Sclafani, AP; McCormick, SA, Induction of Dermal Collagenesis, Angiogenesis, and Adipogenesis in Human Skin by Injection of Platelet-Rich Fibrin Matrix, Archives of Facial Plastic Surgery, 2011:10.
SOURCE Aesthetic Factors, LLC